This is a non-core endpoint: only basic statistics are computed.
Benign neoplasm: Bone and articular cartilage, unspecified
CD2_BENIGN_BONE_CARTILAGE_NOS_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleNone |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Bone and articular cartilage, unspecified
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm: Bone and articular cartilage, unspecified
- Benign neoplasm of bone and articular cartilage
- Benign neoplasm of bone and articular cartilage
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 275 | 158 | 117 |
| Unadjusted period prevalence (%) | 0.05 | 0.05 | 0.05 |
| Median age at first event (years) | 38.62 | 38.37 | 38.96 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 245
- Matched controls
- 2450
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D16.90
ICD-10 Finland
Bone and articular cartilage, unspecified
+∞
168.9
142
*
21309
ICD-8 Finland
Benign neoplasm of bone and cartilage, Unspecified
+∞
45.2
42
*
21308
ICD-8 Finland
Benign neoplasm of bone and cartilage, Loco alio sive multiplici
+∞
34.2
32
*
2139X
ICD-9 Finland
Benign neoplasm of bone and articular cartilage, Bone and articular cartilage, site unspecified
+∞
20.1
19
*
130
Kela drug reimbursment
Malignant tumour
+∞
13.7
13
*
D48.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bone and articular cartilage
19.6
13.6
20
11
AAP10
NOMESCO Finland
Extirpation of a skull lesion
+∞
12.6
12
*
9102
FHL
Trepanation or removal of the local bone process
29.5
10.8
14
5
D16.49
ICD-10 Finland
Bones of skull and face
+∞
10.5
10
*
NDR20
NOMESCO Finland
Incomplete excision of soft tissue tumour of wrist or hand
21.1
9.9
14
7
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
9.4
9
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
9.4
9
*
D16.0
ICD-10 Finland
Benign neoplasm: Scapula and long bones of upper limb
+∞
9.4
9
*
D16.1
ICD-10 Finland
Benign neoplasm: Short bones of upper limb
+∞
9.4
9
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
9.4
9
*
H02AB02
ATC
dexamethasone; systemic
13.4
8.5
14
11
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
8.4
8
*
D16.9
ICD-10 Finland
Benign neoplasm: Bone and articular cartilage, unspecified
+∞
8.4
8
*
115
Kela drug reimbursment
Breast cancer
+∞
8.4
8
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
8.4
8
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
8.4
8
*
D16.2
ICD-10 Finland
Benign neoplasm: Long bones of lower limb
19.1
7.7
11
6
WF002
NOMESCO Finland
Radical radiotherapy
+∞
7.3
7
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
7.3
7
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
+∞
7.3
7
*
NFR20
NOMESCO Finland
Incomplete excision of soft tissue tumour of hip or thigh
+∞
7.3
7
*
D16.91
ICD-10 Finland
Benign tumor in unspecified localization in bone with urpsrung in teeth
+∞
7.3
7
*
JN4BD
NOMESCO Finland
Extensive body CT
4.9
6.4
20
44
L02BG04
ATC
letrozole; oral
18.6
6.3
9
5
L01BC06
ATC
capecitabine; oral
+∞
6.3
6
*
HA003
NOMESCO Finland
Radiotherapy after partial ablation of mammary gland
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
129
901
1.81
5.49
4.7
5.8
1.2
1.2
mmol/l
0.04
112
778
116
812
1.74
4.71
4.0
5.3
1.2
1.2
mmol/l
0.01
100
729
153
1175
1.68
4.29
3.6
4.3
6.4
6.6
mmol/l
0.64
137
1082
193
1578
1.75
4.28
7.7
5.0
74.7
74.7
u/l
0.00
185
1454
65
395
1.85
4.19
1.4
1.3
5.4
8.5
u/ml
0.27
26
153
80
522
1.75
4.06
2.2
2.2
320.1
4318.3
umol/l
1.59
72
464
67
417
1.80
3.98
1.5
1.3
55.7
27.9
iu/ml
0.28
26
131
126
980
1.53
2.98
6.3
3.6
12.8
11.2
umol/l
0.33
121
910
85
615
1.55
2.76
3.2
2.0
2.4
2.3
mmol/l
0.22
75
528
6
10
6.10
2.71
1.8
1.3
0.8
1.0
g/l
—
6
10
40
240
1.78
2.66
5.8
6.1
—
—
—
0
0
9
25
3.69
2.60
1.9
1.5
—
—
—
0
0
242
2216
1.77
2.46
13.5
10.7
20.0
20.4
mg/l
0.09
201
1650
102
788
1.47
2.37
4.4
3.6
36.7
36.4
g/l
0.17
97
734
29
165
1.85
2.30
3.1
2.4
370.6
227.8
u/l
0.75
29
154
139
1146
1.43
2.26
9.5
6.5
4.0
4.1
e9/l
0.22
121
995
244
2254
1.73
2.21
13.8
12.5
3.9
4.0
mmol/l
0.37
238
2184
189
1654
1.46
2.18
4.4
3.7
9.6
10.2
mm/h
0.25
176
1532
62
439
1.53
2.18
2.2
1.9
—
—
—
0
0
8
25
3.26
2.11
1.0
1.7
—
—
—
0
0
243
2249
1.69
2.09
13.8
12.4
139.6
139.7
mmol/l
0.45
236
2183
87
666
1.45
2.08
2.9
2.8
—
—
—
0
0
10
38
2.69
2.03
1.8
2.6
—
—
—
0
0
10
39
2.62
1.94
1.6
1.3
—
—
—
0
0
33
211
1.64
1.78
1.9
4.9
1.1
1.0
mmol/l
0.97
33
190
83
647
1.41
1.77
1.7
2.1
296.9
176.1
u/l
0.68
75
603
191
1706
1.39
1.74
4.0
3.8
14.4
14.6
pmol/l
0.39
174
1569
98
796
1.36
1.61
2.8
3.2
81.1
42.8
ng/l
0.30
63
497
7
26
2.74
1.59
1.3
1.2
—
—
—
0
0
44
313
1.48
1.52
2.4
2.4
3.8
1.0
e6/l
0.52
26
165
9
37
2.48
1.49
3.3
1.8
52.3
13.2
u/ml
—
9
31
68
528
1.38
1.47
2.7
2.6
0.1
0.4
e6/l
2.04
57
383
5
16
3.16
1.44
1.0
1.1
—
—
—
0
0
222
2061
1.40
1.40
4.8
4.5
1.7
2.4
mu/l
0.73
207
1915
108
909
1.31
1.36
4.1
3.7
—
—
—
0
0
13
69
1.93
1.31
1.0
1.1
—
10.8
—
0
10
23
148
1.60
1.25
1.7
1.8
74.0
70.0
ml/min/173m2
—
9
61
62
489
1.35
1.21
1.4
1.6
0.7
1.0
mg/l
1.30
48
367
37
267
1.45
1.21
1.3
1.7
—
—
—
0
0
40
294
1.42
1.19
2.5
2.6
4.4
2.8
e6/l
0.53
22
147
101
857
1.28
1.17
2.2
2.3
74.1
75.1
nmol/l
0.14
92
771
13
73
1.82
1.13
2.3
1.2
—
—
—
0
0
13
73
1.82
1.13
2.3
1.2
4.8
3.9
g/l
—
8
54
13
73
1.82
1.13
2.3
1.2
7.8
7.5
g/l
—
8
57
18
112
1.65
1.12
1.4
1.5
—
—
—
0
0
46
351
1.37
1.11
2.7
2.0
2.4
2.4
mmol/l
0.88
40
295
67
548
1.29
1.02
3.4
3.3
0.0
0.0
estimate
0.80
21
185
24
165
1.50
1.01
1.9
2.5
1.8
2.2
mmol/l
0.26
18
125
65
534
1.28
0.96
2.0
2.8
495.3
1185.7
ng/l
2.73
50
435
0
32
0.00
0.95
0.0
1.3
—
—
—
0
0
6
27
2.25
0.94
1.0
1.1
—
—
—
0
0
6
27
2.25
0.94
2.7
2.1
14.0
13.3
%
—
6
27
26
185
1.45
0.93
1.3
1.7
—
—
—
0
0
62
513
1.27
0.86
1.4
1.3
5.1
1.4
u/ml
0.43
20
139
11
65
1.72
0.83
1.1
1.1
—
—
—
0
0
11
65
1.72
0.83
1.1
1.1
—
—
—
0
0
219
2079
1.26
0.81
11.5
9.3
84.2
84.4
ml/min/173m2
0.05
176
1656
10
58
1.75
0.80
1.3
1.2
—
—
—
0
0
7
38
1.86
0.74
1.4
1.3
398.0
11.6
u/l
—
7
33
25
186
1.38
0.73
1.3
1.8
—
—
—
0
0
12
76
1.61
0.73
1.3
1.6
—
—
—
0
0
47
386
1.26
0.70
1.3
1.5
—
—
—
0
0
43
350
1.27
0.69
1.4
1.7
1106.8
1183.1
nmol/l
0.26
34
272
17
119
1.46
0.68
1.1
1.0
—
—
—
0
0
5
29
1.74
0.64
1.2
1.2
—
—
—
0
0
9
141
0.63
0.62
1.3
1.5
—
—
—
0
0
168
1575
1.17
0.61
3.6
2.9
48.1
41.9
u/l
0.40
161
1486
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
0
20
0.00
0.60
0.0
1.1
—
—
—
0
0
0
20
0.00
0.60
0.0
1.6
—
3.0
—
0
9
0
22
0.00
0.59
0.0
1.1
—
—
—
0
0
0
23
0.00
0.58
0.0
1.0
—
1.0
—
0
15
163
1532
1.16
0.55
3.3
3.3
—
—
—
0
0
92
829
1.16
0.54
3.3
3.1
—
—
—
0
0
6
40
1.51
0.52
1.2
1.3
—
—
—
0
0
6
40
1.51
0.52
1.2
1.3
—
—
—
0
0
113
1041
1.15
0.49
3.3
3.1
0.0
0.0
estimate
0.00
22
182
8
57
1.42
0.42
1.8
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
37.3
—
0
10
0
15
0.00
0.41
0.0
4.1
—
—
—
0
0
11
149
0.73
0.41
6.9
6.8
1.1
1.3
mmol/l
1.34
11
142
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
9
66
1.38
0.39
1.1
1.8
—
—
—
0
0
5
36
1.40
0.38
3.0
1.6
—
—
—
0
0
244
2390
1.19
0.35
11.1
8.0
26.9
26.0
u/l
0.44
235
2308
6
44
1.37
0.34
1.2
1.2
—
—
—
0
0
20
164
1.24
0.33
2.3
1.9
—
—
—
0
0
113
1065
1.10
0.32
3.3
3.1
0.0
0.0
estimate
0.00
23
179
224
2186
1.13
0.31
4.0
4.2
5.7
5.9
mmol/l
1.11
206
2011
29
250
1.18
0.31
4.1
4.4
35.1
31.1
%
1.22
20
168
7
54
1.30
0.30
1.1
1.7
—
—
—
0
0
90
840
1.11
0.30
2.0
1.9
98.3
96.5
pmol/l
0.11
52
432
111
1048
1.10
0.30
4.5
4.3
0.0
0.0
estimate
0.50
23
183
16
131
1.24
0.28
2.1
1.8
—
—
—
0
0
8
64
1.26
0.27
1.1
1.7
—
—
—
0
0
15
122
1.24
0.27
1.1
1.3
—
—
—
0
0
43
387
1.13
0.27
2.6
3.8
437.5
271.6
ng/l
0.20
31
286
8
66
1.22
0.27
1.1
1.1
—
—
—
0
0
203
2081
0.91
0.27
5.1
5.3
38.7
39.5
mmol/mol
0.59
192
1958
5
74
0.67
0.26
1.8
1.7
—
—
—
0
0
47
515
0.89
0.25
4.4
3.1
17.7
25.2
%
3.46
24
200
10
78
1.29
0.24
2.6
1.9
—
—
—
0
0
36
323
1.13
0.24
1.6
1.7
1.4
1.5
%
0.28
30
285
7
92
0.75
0.23
1.3
1.4
—
—
—
0
0
61
568
1.10
0.22
1.8
1.6
1.3
1.4
mmol/l
0.45
53
487
48
442
1.10
0.21
1.3
1.6
—
—
—
0
0
8
103
0.77
0.21
2.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
2.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
1782.9
—
0
12
192
1875
1.08
0.20
17.3
12.9
13.8
13.5
%
0.68
185
1836
214
2099
1.09
0.20
15.6
11.7
39.8
40.7
%
0.93
169
1612
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.7
—
—
—
0
0
6
51
1.18
0.19
2.0
1.3
—
—
—
0
0
214
2174
0.93
0.16
3.6
3.8
1.2
1.3
mmol/l
1.77
196
2024
62
654
0.93
0.15
5.1
3.3
1.7
1.7
ug/l
0.03
57
580
21
188
1.13
0.15
5.6
9.8
1.6
1.6
mmol/l
0.02
16
143
39
366
1.08
0.12
3.1
2.4
1.3
0.7
ug/l
0.40
25
213
222
2246
0.94
0.12
4.0
4.2
1.5
1.5
mmol/l
0.56
203
2104
5
61
0.82
0.08
1.6
1.3
—
41.0
—
0
7
5
64
0.78
0.08
1.4
1.5
—
—
—
0
0
8
74
1.08
0.07
1.5
1.4
—
—
—
0
0
7
84
0.83
0.07
4.1
1.9
—
—
—
0
0
30
289
1.04
0.04
1.8
1.9
—
—
—
0
0
26
250
1.04
0.03
1.6
1.7
—
—
—
0
0
10
92
1.09
0.03
1.1
1.7
—
—
—
0
0
17
178
0.95
0.02
3.3
2.6
—
—
—
0
0
47
478
0.98
0.01
1.5
1.5
18.5
21.1
nmol/l
0.74
39
422
33
323
1.02
0.01
2.0
2.1
—
—
—
0
0
225
2257
0.98
0.01
4.2
4.2
4.7
4.7
mmol/l
0.20
203
2120
229
2291
1.00
0.00
4.7
4.7
2.7
2.8
mmol/l
0.33
212
2140
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
5
52
0.96
0.00
2.6
1.6
134.2
256.2
pmol/l
—
5
47
7
79
0.88
0.00
9.4
11.4
25.1
25.0
mmol/l
—
7
72
0
5
0.00
0.00
0.0
6.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
8
85
0.94
0.00
1.8
2.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_BONE_CARTILAGE_NOS_EXALLC – Benign neoplasm: Bone and articular cartilage, unspecified
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).